- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00992992
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
November 19, 2019 updated by: GlaxoSmithKline
Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma
The primary efficacy endpoint of this study is to determine the duration of response of the sequential administration of Iodine-131 Anti-B1 Antibody followed by six cycles of CHOP for patients with previously untreated Mantle Cell Lymphoma (MCL).
The secondary efficacy endpoints for this study are to determine the response rate, confirmed response rate, complete response rate, confirmed complete response rate, duration of response for confirmed responders, duration of response for complete responders, duration of response for confirmed complete responders, progression-free survival, time to treatment failure, and the predictive value of detection of minimal residual disease by molecular techniques on response duration.
The pharmacokinetic endpoint is to determine the total body residence time of Iodine-131 Anti-B1 Antibody following the dosimetric dose.
The safety endpoints are to determine the incidence of adverse experiences, hematologic toxicity, (e.g., nadir, time to nadir, and time to recovery), use of supportive care, percent of patients converting to human anti-murine antibody (HAMA) positivity, the effects of Iodine-131 Anti-B1 Antibody on the growth and function of hematopoietic progenitor cells, and survival of patients with previously untreated MCL treated with Iodine-131 Anti-B1 Antibody followed by six cycles of CHOP.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have a confirmed initial diagnosis of mantle cell non-Hodgkin's lymphoma by histology according to the WHO classification .
- Patients must have Ann Arbor bulky stage II, stage III, or stage IV disease at diagnosis. Bulky stage II disease is defined as a mediastinal mass greater than one-third of the maximum chest diameter, or any other mass greater than or equal to 10 cm in maximum diameter.
- Patients must have less than an average of 25% of the intratrabecular marrow space involved by NHL in bilateral bone marrow biopsy specimens as assessed microscopically at study entry. A unilateral bone marrow biopsy demonstrating <10% involvement with NHL is also adequate.
- Patients must have evidence that their tumor tissue expresses the CD20 antigen. Immunoperoxidase stains of paraffin-embedded tissue showing positive reactivity with L26 antibody or immunoperoxidase stains of frozen tissue showing positive reactivity with Anti-B1 Antibody (Coulter Clone) or similar commercially available CD20 antibody or evidence of CD20 positivity by flow cytometry are acceptable evidence of CD20 positivity. This must be performed within 42 days of study entry.
- Patients must have a performance status of at least 60% on the Karnofsky Performance Scale and an anticipated survival of at least 3 months.
- Patients must have an ANC greater than or equal to 1500 cells/mm3 and a platelet count greater than or equal to 100,000 cells/mm3 within 14 days of study enrollment. These blood counts must be sustained without support of hematopoietic cytokines or transfusion of blood products.
- Patients must have adequate renal function (defined as serum creatinine <1.5 times the upper limit of normal) and hepatic function (defined as total bilirubin <1.5 times the upper limit of normal and AST <5 times the upper limit of normal) within 14 days of study enrollment.
- Patients must have bi-dimensionally measurable disease. At least one lesion must be greater than or equal to 2.0 x 2.0 cm by computerized tomography scan.
- Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment.
- Patients must have a cardiac left ventricular ejection fraction of greater than or equal to 50% by ventriculography or echocardiogram.
Exclusion Criteria:
- Patients who have received prior chemotherapy, biologic therapy, steroids, or radiation therapy as treatment for their MCL
- Patients with active obstructive hydronephrosis
- Patients with serious illness that would preclude evaluation
- Patients with prior malignancy other than lymphoma, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for 5 years
- Patients with known HIV infection
- Patients who are HAMA positive
- Patients with known brain or leptomeningeal metastases.
- Patients who are pregnant or breastfeeding. Males and females must agree to use a contraceptive method while on study and for 6 months after receiving Iodine-131 Anti-B1 Antibody.
- Patients with active infection requiring IV anti-infectives at the time of study enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tositumomab and Iodine I 131 Tositumomab followed by CHOP
|
Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose).
Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose.
Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose).
Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass.
Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With the Indicated Unconfirmed Response (Complete Response, Complete Response Unconfirmed, and Partial Response)
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Participants with response include those with complete response (CR: complete disappearance of all detectable clinical and radiographic evidence of disease and the disappearance of all disease-related symptoms), complete response unconfirmed (CRu: CR, with one of the following: residual lymph node mass >1.5 centimeters [cm] that has regressed by more than 75% in the sum of the product of the diameters or indeterminate bone marrow), or partial response (PR: >=50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions; no new lesions).
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With the Indicated Confirmed Response (Confirmed Complete Response, Complete Response Unconfirmed, and Partial Response)
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
A confirmed response is defined as a response that was confirmed by two separate response evaluations occurring at least 4 weeks apart.
Participants with a confirmed response include those with complete response (CR: complete disappearance of all detectable clinical and radiographic evidence of disease and the disappearance of all disease-related symptoms), complete response unconfirmed (CRu: CR, with one of the following: residual lymph node mass >1.5 cm that has regressed by more than 75% in the sum of the product of the diameters or indeterminate bone marrow), or partial response (PR: >=50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions; no new lesions).
The individual rows for confirmed CR, confirmed CRu, and confirmed PR represent confirmation of the same response.
For example, a confirmed CR indicates that a CR was followed by another CR at least 4 weeks later.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Duration of Response for All Confirmed Responders (CR + CRu + PR)
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Complete response (CR) is defined as the complete disappearance of all detectable clinical and radiographic evidence of disease and the disappearance of all disease-related symptoms.
Complete response unconfirmed (CRu) is defined as CR, with one of the following: residual lymph node mass >1.5 cm that has regressed by more than 75% in the sum of the product of the diameters or indeterminate bone marrow.
Partial response (PR) is defined as a >=50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions; no new lesions.
For participants with CR, CRu, or PR, duration of response is defined as the time from the first documented response to the first documented progression.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Duration of Response for All Unconfirmed Responders (CR + CRu + PR)
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Complete response (CR) is defined as the complete disappearance of all detectable clinical and radiographic evidence of disease and the disappearance of all disease-related symptoms.
Complete response unconfirmed is defined as CR, with one of the following: residual lymph node mass >1.5 cm that has regressed by more than 75% in the sum of the product of the diameters or indeterminate bone marrow.
Partial response (PR) is defind as a >=50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions; no new lesions.
Duration of response is defined as the time from the first documented response to the first documented progression.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Duration of Response for Unconfirmed Complete Responders
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Complete response is defined as the complete disappearance of all detectable clinical and radiographic evidence of disease and the disappearance of all disease-related symptoms.
Duration of response is defined as the time from the first documented response to the first documented progression.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Duration of Response for Confirmed Complete Responders
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Complete response is the complete disappearance of all detectable clinical and radiographic evidence of disease and the disappearance of all disease-related symptoms.
A confirmed response is defined as a response that was confirmed by two separate response evaluations occurring at least 4 weeks apart.
Duration of response is defined as the time from the first documented response to the first documented progression.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Progression-free Survival
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Progression-free survival is defined as the time from the start of treatment (i.e., the dosimetric dose) to the first documented disease progression or death.
Disease progression is defined as a >=25% increase from the nadir value of the sum of the products of the longest perpendicular diameters of all measurable lesions or the appearance of any new lesion.
Individual lesions must have been greater than 2 centimeters (cm) in diameter by radiographic evaluation or greater than 1 cm in diameter by physical examination.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Time to Treatment Failure
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Time to treatment failure is defined as the time from the date of the dosimetric dose to the first occurrence of treatment withdrawal, decision to seek additional therapy, study removal, disease progression, alternative therapy, or death.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
SAEs are defined as those events that were fatal or immediately life-threatening, and those events that resulted in hospitalization; prolonged an existing hospitalization; resulted in disability; or was a congenital anomaly.
Refer to the general AE/SAE module for a complete list of all AEs and SAEs.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Mean Nadir Value for Absolute Neutrophil Count (ANC)
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Nadir is defined as the lowest laboratory value recorded following the administration of study medication.
ANC is a measure of the number of neutrophil granulocytes present in the blood.
Neutrophils are a type of white blood cell that fights infection.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Mean Nadir Value for Hemoglobin
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Nadir is defined as the lowest laboratory value recorded following the administration of study medication.
Hemoglobin is the iron-containing oxygen-transport metalloprotein in the red blood cells.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Mean Nadir Values for Platelets and White Blood Cell (WBC) Count
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Nadir is defined as the lowest laboratory value recorded following the administration of study medication.
Platelets and WBCs are types of blood cells.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Time to Nadir for the Indicated Hematology Parameters
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Hematology parameters include ANC (calculated), hemoglobin, platelet count, and WBC count.
Nadir is defined as the lowest laboratory value recorded following the administration of study medication.
Time to nadir is defined as the time from Baseline to the time the lowest value recorded following the therapeutic dose.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Time to Recovery From the Indicated Hematology Parameters
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Hematology parameters include ANC (calculated), hemoglobin, platelet count, and WBC count.
Nadir is defined as the lowest laboratory value recorded following the administration of study medication.
Time to recovery to Baseline for the indicated hematologic parameters is defined as the time required for recovery from nadir values to Baseline values.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Number of Participants Negative for Human Anti-Murine (Mouse) Antibody (HAMA) at Screening Who Converted to HAMA Positivity or Remained Negative During the Course of the Study
Time Frame: Screening; at Week 7, Week 13, then every 6 months until disease progression or death (up to 143 months)
|
The number of participants who developed human anti-murine (mouse) anibodies (HAMA) after treatment was measured.
Conversion to HAMA positivity is relative to Screening (participants were evaluable for HAMA analysis if they were HAMA negative at Screening).
|
Screening; at Week 7, Week 13, then every 6 months until disease progression or death (up to 143 months)
|
Number of Participants With an Adverse Event of Cytopenia
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
The effects of iodine I-131 tositumomab on the growth and function of hematopoietic progenitor cells was measured as the number of participants who had cytopenia.
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Overall Survival
Time Frame: Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Overall survival is defined as the time from the start of treatment to the date of death from any cause.
|
Every 13 weeks up to 2 years, or every 6 months until disease progression or death (average of 77.8 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2001
Primary Completion (Actual)
June 30, 2013
Study Completion (Actual)
June 30, 2013
Study Registration Dates
First Submitted
October 8, 2009
First Submitted That Met QC Criteria
October 8, 2009
First Posted (Estimate)
October 9, 2009
Study Record Updates
Last Update Posted (Actual)
December 4, 2019
Last Update Submitted That Met QC Criteria
November 19, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 393229/005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD for this study will be made available via the Clinical Study Data Request site.
IPD Sharing Time Frame
IPD is available via the Clinical Study Data Request site (click on the link provided below)
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Mantle-Cell
-
Northwestern UniversityNational Cancer Institute (NCI); Janssen Scientific Affairs, LLCActive, not recruitingStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma | Stage II Contiguous Mantle Cell Lymphoma | Stage II Non-Contiguous Mantle Cell LymphomaUnited States
-
Burzynski Research InstituteWithdrawnRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell LymphomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Ann Arbor Stage I Mantle Cell Lymphoma | Ann Arbor Stage II Mantle Cell Lymphoma | Ann Arbor Stage III Mantle Cell Lymphoma | Ann Arbor Stage IV Mantle Cell LymphomaUnited States
-
BeiGeneRecruitingMantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina
-
BeiGeneCompletedRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Central Nervous System Lymphoma | Gastric Mantle Cell Lymphoma | Splenic Mantle Cell LymphomaUnited States
-
Fondazione Italiana Linfomi - ETSRecruitingRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaItaly
Clinical Trials on Tositumomab and Iodine I 131 Tositumomab followed by CHOP
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
University of Michigan Rogel Cancer CenterGlaxoSmithKlineActive, not recruitingMultiple MyelomaUnited States
-
University of NebraskaNational Cancer Institute (NCI); Coulter Pharmaceutical, Inc.Terminated
-
GlaxoSmithKlineCompletedNon-Hodgkin's LymphomaUnited States
-
GlaxoSmithKlineWithdrawnLymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Large-Cell, FollicularUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | Lymphoid Leukemia in RemissionUnited States